Sungkyunkwan University

성균관대학교 로고

Truly, Global Leading University SKKU
메뉴버튼

성균관대학교 로고

Truly, Global Leading University SKKU
검색버튼
search form

성균관대학교 로고

메뉴닫기

SKKU News

home Campus Life SKKU NewsSKKU News

게시물 상세보기
TITLE Prof. Yong Taik LIM Develops Implantation of Synthetic Immune Niche that Prevents Tumor Recurrance
POSTER 김민선 NO 2490
DATE 2018.04.11 17:06:02 HIT 878

Cancer vaccines are an attractive option for improving disease-free survival following surgical resection of solid tumors. However, several clinical studies have shown that while cancer vaccines can routinely induce protection in a prophylactic model, the same vaccines often show only limited therapeutic efficacy. The tumor immunosuppressive network, formed by interactions between cancer cells and host immune cells, is a major obstacle to achieving complete tumor eradication. Myeloid-derived suppressor cells (MDSCs) can be considered critical players in tumor-induced immunosuppression in both animal models and cancer patients, which they have a remarkable ability to suppress the activation and proliferation of T cells. Therefore, the depletion of MDSCs would strengthen immunity of tumor-bearing mice.

 

Recently, Prof. Yong Taik LIM’s group of Sungkyunkwan University reported a novel implantable, engineered 3-dimensional porous scaffolds which were designed to generate synergistic action between MDSC-depleting agents and cancer vaccines consisting of whole tumor lysates and nanogel-based adjuvants. The local peritumoral implantation of the synthetic immune niche (termed immuneCare-DISC, iCD) as a post-surgical treatment in an advanced-stage primary 4T1 breast tumor model generated systemic anti-tumor immunity and prevented tumor recurrence at the surgical site as well as the migration of residual tumor cells into the lungs, resulting in 100% survival.

 

These therapeutic outcomes were achieved through the inhibition of immunosuppressive MDSCs in tumors and spleens by releasing gemcitabine and recruitment/activation of dendritic cells, enhanced population of CD4+ and CD8+ T cells, and increased IFN-γ production by cancer vaccines from the iCD. This combined spatiotemporal modulation of tumor-derived immunosuppression and vaccine-induced immune stimulation through the iCD is expected to provide an immune niche for preventing of postoperative tumor recurrence and metastasis.

 

          Figure 1. Schematic diagram showing the design of the immuneCare-DISC

PREV/NEXT
PREV Prof. Chun Gwon Park (GBME) develops an immunotherapy technology that can prevent cancer recurrence
NEXT A research group of Prof. In Su KIM decorated the cover paper of JACS
vision 2020
  • Global Power Elite
  • Research with Impact
  • Globally First Choice
  • Pride in Top
HUMANITIES AND SOCIAL SCIENCES CAMPUS: (03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA
NATURAL SCIENCES CAMPUS: (16419) 2066, SEOBU-RO, JANGAN-GU, SUWON-SI, GYEONGGI-DO, KOREA

COPYRIGHT ⓒ 2014 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED. Contact us